BoFA Lowers PT on Recursion Pharmaceuticals (RXRX), Keeps a Hold Rating

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Low Risk Penny Stocks to Buy Now. On February 27, Bank of America Securities reiterated a Hold rating on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) but lowered the price target from $7 to $6.

​The firm said in a research note that the company has yet to prove that its AI‑driven operating system can reliably generate differentiated drug candidates and meaningful patient outcomes. BofA noted that Recursion can do this through repeated wins in clinical trials. The firm highlighted that FAP data readout for REC‑4881 is a solid start; however, the clinical data from the program is expected to materialize in 2027.

​BofA noted that the company’s cash burn discipline and partnership remain positive components, but upcoming pipeline readouts are considered the main catalysts for building more confidence in the market.

​Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) operates as a clinical-stage biotechnology company that decodes biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the US.